Breaking AI & Tech News Analyzed

In a viral trend on TikTok, Londoners are reviewing upmarket bakeries and cafes in their neighborhoods, sparking conversations about gentrification and the changing face of local businesses.Moses Combe, a 21-year-old from north London, started a series of videos called the 'Endz Department for Research', where he reviews upscale cafes that he wouldn't normally visit. His goal is to investigate the changes happening in his own backyard. Combe's review of Jolene, a bakery he describes as 'giving Gail's Pro Max', comes to £14.20. He enjoys the sausage roll, saying 'They did not skimp out with that sausage, bro.'Combe isn't alone in his reviews. Kobi Coker, a 27-year-old comedian and educator, also reviews 'gentrified' spaces. He says his videos exploring these areas weren't initially intentional but were sparked by noticing new, upmarket establishments opening up on his road during his daily commute. Coker has reviewed the Dusty Knuckle bakery, Jolene, Gail's, and Pret, often joking about his experiences.The trend has led to discussions about gentrification and its impact on local businesses. Coker notes that while some new businesses bring new ideas, the problem is that long-time residents 'aren't necessarily able to participate in it.' Matthew Roberts, operations manager at Jolene, welcomes the attention, saying it's 'all very positive' and that they want to 'welcome absolutely everybody.'Other reviewers, like Daniel Poon, a 27-year-old content creator, review mainstream chains when they release products inspired by other cuisines. He reviewed Pret's ube drink, saying it didn't feel authentic to the original Filipino flavor. Poon appreciates chains' efforts to branch out and try new things, but also values diversity and trying different cuisines.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

Science is often seen as a dry and serious field, but does it have to be? A recent study published in Proceedings of the Royal Society B found that scientists deliver an average of only 1.6 jokes per presentation, with 66% generating only polite chuckles.The findings confirm previous research, including a randomized clinical trial conducted over 20 years ago by Timandra Harkness and Helen Pilcher under the guise of the Comedy Research Project. The study found that laughter levels failed to reach statistical significance, even when scientists attempted to incorporate humor into their talks.However, research suggests that humor can be an effective tool in science communication. A 2025 study called Wit Meets Wisdom found that humor can boost credibility and likability, making researchers seem more trustworthy and their findings less likely to be disputed.Helen Pilcher, a science writer and author, argues that scientists should not be afraid to adopt a more playful tone when communicating their research. By incorporating humor, scientists can build cohesion and foster a sense of shared perspective with their audience.Pilcher suggests that scientists can use humor to make their research more engaging and memorable, without having to convert it into standup comedy. By doing so, scientists can make their research more accessible and enjoyable for a wider audience.

President Donald Trump has unveiled a bold budget request, seeking $1.5 trillion for military spending, a nearly 40% increase from the previous year. This ambitious proposal underscores the White House's priorities, emphasizing military strength and law enforcement.The budget request, while not legally binding, sets the stage for intense congressional negotiations. It includes a proposed $455 billion increase over fiscal year 2026, separate from an emergency request of $200 billion for the US-Israeli conflict with Iran.The plan involves significant shifts in funding, with $73 billion in cuts to domestic programs, including initiatives to counter climate change, boost renewable energy, and support equality and access in housing, education, and healthcare. Instead, funding would be redirected to projects such as Trump's Golden Dome missile defense system, critical minerals investment, US shipbuilding, and troop salary increases.Trump's proposal also emphasizes immigration enforcement, calling for continued funding for the Department of Homeland Security and Immigration and Customs Enforcement to support his mass deportation campaign. The request includes a 13% increase for the Department of Justice, focusing on violent crime.The budget plan faces challenges, including a potential deadlock in Congress over funding for ICE and Customs and Border Patrol. The administration suggests passing the budget through a mechanism known as reconciliation, which could be achieved with a simple majority in Congress.The US military expenditure has steadily increased, reaching $997 billion in 2024, according to the Stockholm International Peace Research Institute. The country consistently spends more on its military than the next nine countries combined, raising questions about priorities in defense and domestic spending.

The conflict between the US and Israel against Iran has taken a devastating toll on the country's healthcare system. At least 2,076 people have been killed and 26,500 wounded in Iran since the US and Israel first launched strikes on the country on February 28.Iranian President Masoud Pezeshkian has strongly condemned the attacks, appealing to international health organizations to respond to the crisis. On Thursday, he wrote on X: “What message does attacking hospitals, pharmaceutical companies and the Pasteur Institute as a medical research center in Iran convey?”The Pasteur Institute, a key center for medical research and vaccine production in Tehran, has been targeted. The institute, founded over 100 years ago in collaboration with the Institut Pasteur in Paris, conducts research on infectious diseases, produces vaccines, and provides advanced diagnostics.According to the World Health Organization (WHO), over 20 attacks on healthcare facilities in Iran have been verified since March 1, resulting in at least nine deaths, including an infectious diseases health worker and a member of the Iranian Red Crescent Society.Some of the facilities hit include:Red Crescent warehouse in Bushehr province, which was destroyed by a drone strike on Friday morning.Tofigh Daru Research and Engineering Company, one of Iran’s largest pharmaceutical companies, which was hit on March 31.Delaram Sina Psychiatric Hospital in Tehran, which was significantly damaged on March 29.Ali Hospital in Andimeshk, which sustained damage from an explosion on March 21.Gandhi Hospital in Tehran, which was damaged during attacks on a nearby television communications tower on March 2.International humanitarian law states that health establishments and units, including hospitals, should not be attacked. The United Nations Security Council resolution 2286 was adopted unanimously in 2016, condemning attacks on healthcare and calling on nations to respect international law.The attacks on healthcare facilities are not limited to Iran. Israel has also targeted healthcare facilities in Lebanon and Gaza, resulting in significant damage and loss of life.

The conflict between Iran, the United States, and Israel has escalated on day 35, with the US and Israel widening their attacks on Iranian infrastructure. The strikes have targeted a century-old medical research centre in Tehran, steel plants, and a bridge near the capital, which Iran claims was civilian infrastructure.The human toll continues to rise, with at least 2,076 people killed and 26,500 wounded in Iran since the start of the US-Israeli attacks. Iran's Foreign Ministry reports that more than 600 schools and education centres have been hit since February 28.Iran's military has vowed to continue the war until its enemies face 'humiliation' and 'surrender', warning the US against a ground invasion. The Iranian Foreign Ministry has stated that it is ready for any type of attack, including a ground attack.In a significant development, US Defense Secretary Pete Hegseth has abruptly fired the US Army's top general and two other senior officers, sparking speculation of a wartime leadership shake-up.The conflict has also drawn in other countries, with Pakistan pushing for US-Iran talks and the United Kingdom holding talks with about 40 countries on reopening the Strait of Hormuz, which carries about 20 percent of the world's oil and LNG. The US has lost 13 service members in combat and two to noncombat causes, with more than 200 injured.In Israel, sirens have become 'part of life', with residents repeatedly heading to shelters, especially in the Tel Aviv area. The conflict has also intensified along the northern front, with Hezbollah carrying out 60 military operations against Israel in 24 hours.

President Donald Trump escalated rhetoric on Thursday, stating that the United States has yet to begin a full‑scale campaign against Iran’s remaining infrastructure and hinting that bridges and electric power plants could be next targets. The comment followed the release of video showing a U.S. strike on the newly completed B1 bridge that connects Tehran to Karaj, an attack that Iran reports killed eight people and injured 95. Iranian Foreign Minister Abbas Araghchi condemned the strike on civilian infrastructure, describing it as evidence of the “defeat and moral collapse” of the aggressor. In a statement posted on X, he warned that such attacks would not force Iran to surrender. The conflict, now entering its fifth week, has begun to ripple through regional and global markets. Instability around the Strait of Hormuz—a vital conduit for oil and gas—has prompted nations to scramble for alternative shipping routes. Satellite images this week captured smoke over Iran’s Qeshm Island, underscoring the heightened risk to infrastructure near the strategic waterway. Amid stalled negotiations with Iran’s new leadership, Trump’s intensified language comes as the United Nations Security Council prepares to vote on a resolution that could authorize member states to use “defensive means” to keep the strait open. Araghchi warned that any provocative action in the Council would only worsen the situation. Iranian media have begun listing potential retaliation targets, naming major bridges in Kuwait, Saudi Arabia, the United Arab Emirates and Jordan as possible future strike points. The semi‑official Fars News Agency highlighted these crossings as vulnerable following the Karaj bridge attack. The Islamic Revolutionary Guard Corps (IRGC) claimed responsibility for recent strikes on U.S.-linked industrial sites in the Gulf, including steel facilities in Abu Dhabi and aluminium plants in Bahrain. The IRGC warned that if attacks on Iranian industries continue, “the next response will be much more painful” and will focus on the occupier’s core infrastructure. Health infrastructure has also suffered. Iran’s Health Ministry reported that U.S. and Israeli raids severely damaged the Pasteur Institute of Iran, a key research center for diseases such as cholera and COVID‑19. Ministry spokesperson Hossein Kermanpour called the strike “a direct assault on international health security.” WHO Director‑General Tedros Adhanom Ghebreyesus echoed the condemnation, noting that the institute is now unable to deliver health services. The WHO has documented more than 20 attacks on Iranian healthcare facilities since the start of March. In a separate claim, Iranian officials said air defenses downed a second U.S. F‑35 fighter jet over central Iran, suggesting the pilot’s survival was unlikely. The United States has not responded to the allegation. Israel’s military reported a fresh barrage of Iranian missiles, which triggered air‑defence alerts and caused damage to homes, vehicles, and a train station in Tel Aviv. The widening hostilities, combined with threats to critical energy and health infrastructure, highlight the growing regional volatility and its potential to disrupt global markets.

The recent statements and actions by the US, particularly by President Donald Trump, have raised serious concerns about potential war crimes under international law. During a national address, Trump warned that if Iran did not reach a deal with him, the US would target Iranian electric-generating plants and reduce the country to the 'stone ages.'Legal experts and human rights organizations have strongly criticized these threats. Erika Guevara Rosas, Amnesty International's senior director of research, advocacy, policy and campaigns, emphasized that intentionally attacking civilian infrastructure, such as power plants, is generally prohibited under international law. Such actions could cause disproportionate harm to civilians and are considered unlawful and potentially war crimes.More than 100 US experts in international law from prestigious universities, including Harvard, Yale, and Stanford, have expressed similar concerns. They highlighted Trump's comments, including the statement that the US may conduct strikes on Iran 'just for fun,' and Defense Secretary Pete Hegseth's remarks about not fighting with 'stupid rules of engagement.'The experts and legal experts point to the principle of distinction in international humanitarian law, which requires parties to avoid targeting civilian objects. Article 52 of the Geneva Conventions defines civilian objects as those that are not military objectives, and it is a war crime to intentionally direct attacks against them if they are not military objectives.Human rights organizations and experts warn that targeting Iran's power plants would have a devastating impact on the civilian population, affecting hospitals, water supplies, and other vital needs. Sarah Yager, Washington director of Human Rights Watch, noted that such actions would be catastrophic for the Iranian people.